ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1186

The Trajectory of Multimorbidity in Patients with Systemic Lupus Erythematosus in the United States

Ali Duarte-Garcia1, Maria Stevens2, Herbert Heien2, Gabriel Figueroa Parra1, Jose A Meade-Aguilar1, Molly M. Jeffery2, Uma Thanarajasingam1, Cynthia Crowson3 and Rozalina McCoy2, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, 3Mayo Clinic, Eyota, MN

Meeting: ACR Convergence 2022

Keywords: Cohort Study, Epidemiology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Epidemiology and Public Health Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: The presence of multiple chronic conditions (multimorbidity) is associated with disability and premature death. We determined the trajectory of multimorbidity in SLE compared to the general population.

Methods: An SLE cohort was assembled using OptumLabs Datawarehouse (OLDW) from 1/2006-9/2015. SLE cases were identified using > 3 SLE ICD-9 codes separated by > 30 days; the date of the third SLE code was considered the index date. Incident SLE was identified by requiring 12 months without SLE diagnostic codes. Patients with SLE were matched to non-SLE comparators on age, sex, race, region, and enrollment date. Diagnosis codes from the period between enrollment and the end of follow-up (disenrollment or 9/30/2015) were used to determine the presence of comorbidities. We assembled 57 chronic condition categories based on previously described 44 categories (England, B. ARD 2020). The 13 additional categories were added based on the SLICC/ACR damage index (SDI) or otherwise considered relevant to SLE. Two or more ICD-9 codes at least 30 days apart were used to define a comorbidity. We defined multimorbidity as the presence of ≥2 comorbidities (excluding SLE). Conditional logistic regression models were used to compare the prevalence of multimorbidity between cohorts. The trajectory of multimorbidity in people with SLE (vs without SLE) was estimated utilizing generalized estimating equations. We looked at overall trajectory after index date, expanding the observation time one year before index date, and excluding silent conditions to mitigate surveillance bias (hypertension, hypothyroidism, etc.) Odds ratios (OR) and estimates of the linear coefficient and 95% confidence intervals (CI) were reported.

Results: A total of 34,893 SLE patients were matched to 34,893 non-SLE comparators. Of these, 13,531 were incident cases. The mean age was 48 (SD 14.2) years, and 90.6% were female. 66.4% were White, 18.4% Black, 3.4% Asian, and 18.4% Hispanic. From enrollment to the index date, the mean observation time was 2.3 years (SD: 2.4) and 4.4 years (SD: 2.6) for the incident cohort. Multimorbidity was present in 72% of SLE vs. 47% of non-SLE subjects (OR 4.3; 95%CI 4.1-4.5). Patients with SLE had 4.5 comorbidities compared to 2.4 for non-SLE subjects (OR 1.91; 95%CI 1.89-1.94). Compared to baseline, multimorbidity increased among the incident cases, multimorbidity frequency was higher in incident SLE (vs non-SLE) throughout the follow-up compared to baseline (β: 1.85, 95%CI 1.79-1.91). The rate of accrual of chronic conditions was significantly higher in SLE than in non-SLE (Figure 1A; β: 0.63; 95%CI: 0.60-0.65). Patients with SLE had accelerated multimorbidity accrual after excluding silent conditions (Figure 1B). Patients with SLE had increased multimorbidity even one year before SLE onset (Figure 1C).

Conclusion: In this nationwide commercial database insurance study, patients with SLE were four times more likely to suffer from multimorbidity than the general population. Trajectory analysis shows that multimorbidity progresses more rapidly in patients with SLE than those without SLE and may begin before SLE onset.

Supporting image 1

Figure 1: Predicted burden of multimorbidity in incident SLE compared with patients without SLE after diagnosis. Panel A, primary analytical approach requiring 1 year in the data set without SLE diagnostic codes chronic conditions. Panel B, similar analytical approach removing silent conditions. Panel C, restricting the population to individuals with at least 2 years of data prior to index date and beginning follow-up at 1 year before the index date.


Disclosures: A. Duarte-Garcia, None; M. Stevens, None; H. Heien, None; G. Figueroa Parra, None; J. Meade-Aguilar, None; M. Jeffery, None; U. Thanarajasingam, None; C. Crowson, None; R. McCoy, None.

To cite this abstract in AMA style:

Duarte-Garcia A, Stevens M, Heien H, Figueroa Parra G, Meade-Aguilar J, Jeffery M, Thanarajasingam U, Crowson C, McCoy R. The Trajectory of Multimorbidity in Patients with Systemic Lupus Erythematosus in the United States [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-trajectory-of-multimorbidity-in-patients-with-systemic-lupus-erythematosus-in-the-united-states/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-trajectory-of-multimorbidity-in-patients-with-systemic-lupus-erythematosus-in-the-united-states/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology